Insulet (NASDAQ:PODD) Announces Earnings Results, Beats Expectations By $0.40 EPS

Insulet (NASDAQ:PODD) announced its earnings results on Wednesday. The medical instruments supplier reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40, FiscalAI reports. The business had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s revenue was up 19.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.24 earnings per share.

Here are the key takeaways from Insulet’s conference call:

• Third-quarter revenue rose 19.6% in constant currency to $842 million, supported by more than 20% growth in the global customer base. Adjusted operating margin expanded 490 basis points, and adjusted EPS increased 60% year over year.
• Insulet raised its 2026 outlook to the high end of its prior range, expecting 21%–22% constant-currency revenue growth and more than 30% adjusted EPS growth. It also expects approximately 150 basis points of adjusted operating margin expansion.
• Management expects 2027 revenue growth to be modestly below its prior mid-teens framework, with U.S. growth toward the lower end of its earlier range and international growth moderating meaningfully. The company cited tougher comparisons, less international price-mix benefit, new competition, and limited near-term contributions from launches.
• Insulet reported modest improvement in type 2 customer retention after changes to sampling, onboarding, sales incentives, and customer support. Its Omnipod Discover platform has been adopted by more than 35,000 users and 5,000 clinicians, though management said the impact of these efforts will build over time.
• The board approved a $1 billion increase to the share repurchase authorization, with $400 million planned for repurchases in the fourth quarter using cash on hand.

Insulet Price Performance

Insulet stock traded down $11.43 during midday trading on Thursday, hitting $153.59. The company’s stock had a trading volume of 594,433 shares, compared to its average volume of 1,394,444. The stock’s 50-day moving average price is $141.65 and its 200-day moving average price is $178.00. The company has a market capitalization of $10.65 billion, a PE ratio of 28.73, a price-to-earnings-growth ratio of 1.22 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Sanford C. Bernstein raised their price target on Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday. Raymond James Financial restated an “outperform” rating and set a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Benchmark dropped their price objective on shares of Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. BTIG Research downgraded Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Insulet currently has an average rating of “Hold” and a consensus price target of $189.20.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q3 results topped expectations: Insulet reported adjusted EPS of $1.99 versus the $1.59 consensus and revenue of $842 million versus estimates of about $833 million. Revenue grew 19.2% year over year. Insulet Q3 earnings and revenues surpass estimates
• Positive Sentiment: $1 billion share buyback: The repurchase authorization may support demand for shares. Insulet also raised its 2026 outlook, although reports indicate its full-year EPS outlook was maintained. Insulet announces a $1 billion equity buyback
• Neutral Sentiment: Wells Fargo raised its target to $172 from $144 but kept an “equal weight” rating, suggesting the analyst sees some potential upside without making a bullish call. Wells Fargo raises Insulet price target
• Negative Sentiment: 2027 growth risks: The CEO expects slower growth next year and anticipates rivals will take some share from the Omnipod business. Those comments could weigh on expectations despite the strong quarter. CEO discusses slower growth and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.